The negative pressure breathing apparatus developed by a company in central Turkey will allow home treatment for patients suffering from chronic obstructive pulmonary disease (COPD), asthma and lung diseases.
R&D and innovation company Promech, operating in the InnoPark Technology Development Zone in Konya province, rolled out the Rievent, a negative pressure ventilator, in just six months with the support of the Turkish Scientific and Technological Research Council.
Besides allowing patients to breathe comfortably, the device also features a Turkish language menu for its users.
Selcuk Ates, the project manager at Promech, told Anadolu Agency that the device did not require any professional expertise to be used and was designed to be accessible to everyone.
He said the product passed all tests and was now at the certification stage.
Ates explained that at the beginning of the outbreak, the air sacs, also known as alveoli, in the lungs of COVID-19 patients who were put on ventilators were hardening and bursting, causing pneumonia.
“This device eliminates the risk of pneumonia because with it, patients take in as much air as their breathing capacity,” he said, adding that the firm was trying to make Rievent more ergonomic.
“It’s completely a product of local engineering. Its design, software and pattern were made by our company.”
Underlining that mass production was scheduled to start in three months, he said the company would manufacture 100 units per month.
Ates noted that the product would fit the needs of 15 million patients in Turkey. “We aim to reduce the load on hospitals’ intensive care units. The cost of their imports is very high. We want to contribute to the country’s economy by pulling it [costs] down.”
He said the company was successful in tests conducted on 20 volunteers.
“We only couldn’t get the [positive] result we hoped for on obese patients. When the patient starts to breathe normally, the device automatically stops,” Ates said.
*Writing by Jeyhun Aliyev from Ankara
Copyright 2022 Anadolu Agency. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.